Related Experiment Video

Updated: Sep 4, 2025

Prehospital Thrombolysis: A Manual from Berlin
05:52

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

22.0K

Thromboprophylaxis and clinical outcomes in moderate COVID-19 patients: A comparative study

Asmaa S Mohamed1, Hosam M Ahmad2, Alyaa S A Abdul-Raheem3

  • 1Clinical Pharmacy Department, Faculty of Pharmacy, Port Said University, Port Said, Egypt.

Research in Social & Administrative Pharmacy : RSAP
|July 21, 2022
PubMed

Insights

Enoxaparin and rivaroxaban showed similar efficacy and safety for preventing blood clots in moderate COVID-19 patients. Neither anticoagulant demonstrated a clear advantage in clinical outcomes or complications.

Area of Science:

  • Internal Medicine
  • Pharmacology
  • Infectious Diseases

Background:

  • Coronavirus disease 2019 (COVID-19) is associated with a high risk of thrombotic complications.
  • Antithrombotic therapy is crucial for preventing these events in COVID-19 patients.

Purpose of the Study:

  • To compare the efficacy and safety of enoxaparin versus rivaroxaban for thromboprophylaxis in moderate COVID-19.
  • To evaluate clinical outcomes, including mortality and complication rates, between the two anticoagulant groups.

Main Methods:

  • A study involving 124 patients with moderate COVID-19 (pneumonia without hypoxia).
  • Patients were randomized to receive either enoxaparin (0.5 mg/kg SC every 12h) or rivaroxaban (10 mg orally once daily) until hospital discharge.
  • Outcomes assessed included ICU transfer, length of stay, mortality, and thrombotic/bleeding complications.

Main Results:

  • No significant differences were found in intermediate care unit (IMCU) duration, ICU duration, or total hospital stay between enoxaparin and rivaroxaban groups.
  • The rates of ICU admission, in-hospital mortality, thrombotic complications, and mild bleeding were comparable between the two treatment arms.
  • Specific p-values indicated no statistically significant variations in any of the primary or secondary outcomes.

Conclusions:

  • Enoxaparin and rivaroxaban can be utilized as effective thromboprophylaxis agents in patients with moderate COVID-19.
  • Current evidence suggests no definitive advantage of one agent over the other in this patient population.
Abstract

Keywords:
AnticoagulantsCOVID-19EnoxaparinRivaroxabanThromboprophylaxis

More Related Videos

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug07:50

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

Published on: June 4, 2021

2.8K
Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients04:56

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

839

Related Concept Videos

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
30
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
40
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
19
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
21
Pulmonary Embolism III: Nursing Management01:27

Pulmonary Embolism III: Nursing Management

A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
33
Pulmonary Embolism I: Introduction01:29

Pulmonary Embolism I: Introduction

Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
42